Article Text

Download PDFPDF

OP-10 The rationale for the use of microbial keratitis drug delivery protocols
  1. John Dart1,2,
  2. Darwin Minassian3,4
  1. 1Moorfields Eye Hospital NHS Foundation Trust, London, UK
  2. 2National Institute of Health Research (NIHR) Moorfields Biomedical Research Centre, London, UK
  3. 3EpiVision Ophthalmic Epidemiology Consultants, Penn, UK
  4. 4UCL Institute of Ophthalmology, London, UK
  5. *


Introduction Currently there is only one evidence based and published microbial keratitis protocol, the TST (Topical, Systemic, and Targeted Therapy) protocol, which is for use for use in fungal keratitis. Treatment guidelines, without supporting evidence for outcomes are widely used but seldom audited for adherence and results. The current situation is exemplified by the widely disseminated American Academy of Ophthalmology Bacterial Keratitis Preferred Practice Pattern which reviews a swathe of publications but provides few details for the key decision making points in the treatment of bacterial keratitis other than choice of initial treatment.

Key decisions are causative organism dependent and are required for the following: initial treatment; the application frequency for the intensive treatment phase and its length; how to reduce the intensive frequency to one specified for maintenance therapy until defined cure criteria are reached; the time point at which treatment failure should be considered requiring re-evaluation of both diagnosis and treatment; second line adjunctive or alternative topical/systemic antimicrobial therapy; use of adjunctive steroids both when being applied at baseline (point of diagnosis and start of antimicrobial therapy) or later; how to withdraw steroid; management of recurrences of infection or inflammation; when to use cross linking, photodynamic therapy or therapeutic keratoplasty.

Evidence will be given to show how the use of such a detailed protocol has provided high cure rates in both fungal and protozoal keratitis and how such protocols can be expected to be of benefit to all colleagues managing both common and rare causes of keratitis.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.